Quarterly ResultMay 13, 2026, 04:47 PM
Reviva Pharma Q1 Net Loss Halved to $3.2M; Raises $11.5M Capital
AI Summary
Reviva Pharmaceuticals reported a significant reduction in net loss for the first quarter of 2026, halving to $(3.2) million from $(6.4) million in the prior year, driven by lower operating expenses. The company also substantially improved its cash position, ending the quarter with $22.2 million, following successful capital raises totaling over $11.5 million through public and ATM offerings. A 1-for-20 reverse stock split was completed in March 2026. Despite these improvements, the company noted that its current cash is insufficient for the next 12 months and will require additional fundraising, raising substantial doubt about its ability to continue as a going concern.
Key Highlights
- Net loss for Q1 2026 was $(3,195,987), down from $(6,432,840) in Q1 2025.
- Basic and diluted net loss per share improved to $(0.46) from $(2.61) year-over-year.
- Total operating expenses decreased to $3,271,952 in Q1 2026 from $6,538,167 in Q1 2025.
- Cash and cash equivalents increased to $22,190,231 as of March 31, 2026, from $14,438,792 at December 31, 2025.
- Net cash provided by financing activities was $11,552,735 in Q1 2026, up from $7,271 in Q1 2025.
- The company completed a 1-for-20 reverse stock split on March 9, 2026.
- A public offering in March 2026 generated approximately $8.9 million in net proceeds.
- Sales through an At-The-Market (ATM) offering generated approximately $2.5 million in net proceeds.